215 related articles for article (PubMed ID: 6617725)
1. Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects.
Heller F; Harvengt C
Eur J Clin Pharmacol; 1983; 25(1):57-63. PubMed ID: 6617725
[TBL] [Abstract][Full Text] [Related]
2. Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia.
Kłosiewicz-Latoszek L; Szostak WB
Eur J Clin Pharmacol; 1991; 40(1):33-41. PubMed ID: 2060543
[TBL] [Abstract][Full Text] [Related]
3. Combined effects of probucol and benzafibrate on lipoprotein metabolism and liver cholesteryl ester transfer protein mRNA in cholesterol-fed rabbits.
Ou J; Saku K; Jimi S; Liao YL; Ohta T; Zhang B; Arakawa K
Jpn Circ J; 1999 Jun; 63(6):471-7. PubMed ID: 10406588
[TBL] [Abstract][Full Text] [Related]
4. Plasma lipid concentrations and lecithin:cholesterol acyltransferase activity in normolipidemic subjects given fenofibrate and colestipol.
Heller FR; Desager JP; Harvengt C
Metabolism; 1981 Jan; 30(1):67-71. PubMed ID: 7464555
[TBL] [Abstract][Full Text] [Related]
5. Changes in plasma activities of lipolytic enzymes and lipids of normolipidemic subjects given phenobarbital, a strong microsomal inducer, alone or in combination with fenofibrate.
Heller FR; Desager JP; Harvengt C
Int J Clin Pharmacol Ther Toxicol; 1988 Mar; 26(3):138-42. PubMed ID: 3410596
[TBL] [Abstract][Full Text] [Related]
6. Effects of slow-release bezafibrate on serum lipids, lipoproteins, apolipoproteins, and postheparin lipolytic activities in patients with type IV and type V hypertriglyceridemia.
Saku K; Sasaki J; Arakawa K
Clin Ther; 1989; 11(3):331-40. PubMed ID: 2743372
[TBL] [Abstract][Full Text] [Related]
7. Fibrates and triglyceride metabolism.
Schwandt P
Eur J Clin Pharmacol; 1991; 40 Suppl 1():S41-3. PubMed ID: 2044642
[TBL] [Abstract][Full Text] [Related]
8. Fibric acids: effects on lipids and lipoprotein metabolism.
Grundy SM; Vega GL
Am J Med; 1987 Nov; 83(5B):9-20. PubMed ID: 3318457
[TBL] [Abstract][Full Text] [Related]
9. Comparative study of bezafibrate and fenofibrate in patients with primary hyperlipoproteinaemia.
Tesone PA; Gladstein J; Acuña AM
Curr Med Res Opin; 1985; 9(9):650-7. PubMed ID: 3902379
[TBL] [Abstract][Full Text] [Related]
10. Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action.
Haubenwallner S; Essenburg AD; Barnett BC; Pape ME; DeMattos RB; Krause BR; Minton LL; Auerbach BJ; Newton RS; Leff T
J Lipid Res; 1995 Dec; 36(12):2541-51. PubMed ID: 8847480
[TBL] [Abstract][Full Text] [Related]
11. Bezafibrate increases prebeta 1-HDL at the expense of HDL2b in hypertriglyceridemia.
Miida T; Sakai K; Ozaki K; Nakamura Y; Yamaguchi T; Tsuda T; Kashiwa T; Murakami T; Inano K; Okada M
Arterioscler Thromb Vasc Biol; 2000 Nov; 20(11):2428-33. PubMed ID: 11073848
[TBL] [Abstract][Full Text] [Related]
12. Diurnal lipid and lipoprotein profiles with bezafibrate and clofibrate in healthy volunteers.
Oster P; Schlierf G; Lang PD; Mordasini R; Vollmar J
Pharmatherapeutica; 1985; 4(5):267-77. PubMed ID: 4070320
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients.
Franceschini G; Favari E; Calabresi L; Simonelli S; Bondioli A; Adorni MP; Zimetti F; Gomaraschi M; Coutant K; Rossomanno S; Niesor EJ; Bernini F; Benghozi R
J Clin Lipidol; 2013; 7(5):414-22. PubMed ID: 24079282
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of high-density lipoprotein reduction after probucol treatment: changes in plasma cholesterol esterification/transfer and lipase activities.
Chiesa G; Michelagnoli S; Cassinotti M; Gianfranceschi G; Werba JP; Pazzucconi F; Sirtori CR; Franceschini G
Metabolism; 1993 Feb; 42(2):229-35. PubMed ID: 8474321
[TBL] [Abstract][Full Text] [Related]
15. Effect of short-term treatment with bezafibrate and fenofibrate on biliary lipid metabolism in patients with hyperlipoproteinaemia.
von Bergmann K; Leiss O
Eur J Clin Invest; 1984 Apr; 14(2):150-4. PubMed ID: 6428905
[TBL] [Abstract][Full Text] [Related]
16. Comparative ultrastructural study of rat hepatocytes after treatment with the hypolipidemic agents probucol, clofibrate, and fenofibrate.
Barnard SD; Molello JA; Caldwell WJ; LeBeau JE
J Toxicol Environ Health; 1980 May; 6(3):547-57. PubMed ID: 7420463
[TBL] [Abstract][Full Text] [Related]
17. Effect of clofibrate on postheparin plasma triglyceride lipase activities in patients with hypertriglyceridemia.
Nikkilä EA; Huttunen JK; Ehnholm C
Metabolism; 1977 Feb; 26(2):179-86. PubMed ID: 834151
[TBL] [Abstract][Full Text] [Related]
18. [Comparative study of the effects of probucol, fenofibrate and clofibrate on liver ultrastructure in rats (author's transl)].
Barnard SD; Molello JA; Caldwell WJ; Lebeau JE
Nouv Presse Med; 1980 Oct; 9(40):3005-7. PubMed ID: 7443440
[TBL] [Abstract][Full Text] [Related]
19. Hypertriglyceridemia and hyperuricemia: effects of two fibric acid derivatives (bezafibrate and fenofibrate) in a double-blind, placebo-controlled trial.
Bastow MD; Durrington PN; Ishola M
Metabolism; 1988 Mar; 37(3):217-20. PubMed ID: 3278190
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of highly water-soluble fibrate derivatives via BGLation.
Nemoto H; Kamiya M; Nakamoto A; Matsushita T; Matsumura K; Hattori H; Kawamura T; Taoka C; Abe S; Ishizawa K; Miyamoto L; Tsuchiya K
Bioorg Med Chem Lett; 2012 Oct; 22(20):6425-8. PubMed ID: 22975299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
